LGALS3 and Peritoneal Fibrosis: By intersecting the drug targets associated with SAL with the targets related to peritoneal fibrosis, we identified potential therapeutic targets for SAL against peritoneal fibrosis, identifying a total of 4 targets (Figure 4C): cathepsin S (CTSS), VDR, plasminogen activator urokinase (PLAU), and galectin 3 (LGALS3).